Compare ADMA Biologics Inc (ADMA) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs NRG Energy Inc — how do they compare? ADMA Biologics Inc trades at $8.79 (market cap $1.97B), while NRG Energy Inc trades at $125.54 (market cap $28.80B). The key difference: NRG Energy Inc is far larger — about 14.6× ADMA Biologics Inc's market cap, and NRG Energy Inc pays a 1.39% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NRG | |
|---|---|---|
Market Cap | $1.97B | $28.80B |
Sector | Health | Utilities |
52-Week High | $20.38 | $184.03 |
52-Week Low | $7.60 | $120.65 |
Enterprise Value | $2.03B | $52.63B |
Dividend Yield | — | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $8.48, up 2.54% today, but faces a bearish technical signal with moving averages indicating selling pressure. The company shows strong profitability with a 32.43% net income margin and 43.3% ROE, though recent earnings have been mixed with one beat and two misses. A significant overhang is the multiple class action lawsuits filed in late July 2026 alleging securities fraud, which has contributed to negative sentiment.
The outlook is highly conflicted; Wall Street analysts maintain a strong buy consensus with a $17.50 price target, implying major upside, but this is starkly contrasted by the active legal challenges and bearish technicals. The primary risk is the resolution of the lawsuits, which could lead to substantial volatility and reputational damage, potentially overshadowing the solid fundamental performance.
NRG Energy (NRG) trades at $127.56, down 9.55% over the past 24 hours amid a bearish technical signal. The stock has shown mixed earnings performance, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Despite a high P/E ratio of 150, the P/S ratio of 0.84 and positive operating cash flow of $1.91 billion in 2025 highlight fundamental strengths. Recent news highlights the company's capital allocation strategy, including a $1.4 billion shareholder return plan for 2026 and expansion into data center power demand.
The outlook for NRG is cautiously optimistic, supported by analyst consensus with a $213 price target and 65% buy ratings. Key opportunities include growth from data center deals and Texas capacity expansions, while risks involve high debt levels, with a debt-to-asset ratio of 56.42% in 2025, and volatile earnings trends. Investors should weigh strong institutional support against execution risks in a competitive utilities sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
